Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

Ryan, D P

doi:10.1158/1078-0432.CCR-0980-3

Record: found
Abstract: not found
Article: not found

Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

Author(s): D. P. Ryan

Publication date Created: April 01 2004

Publication date (Print): April 01 2004

Journal: Clinical Cancer Research

Publisher: American Association for Cancer Research (AACR)

Read this article at

ScienceOpenPublisher

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: Clinical Cancer Research

Abbreviated Title: Clinical Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN (Print): 1078-0432

ISSN (Electronic): 1557-3265

Publication date Created: April 01 2004

Publication date (Print): April 01 2004

Volume: 10

Issue: 7

Pages: 2222-2230

Article

DOI: 10.1158/1078-0432.CCR-0980-3

SO-VID: 948918a0-25d7-49d9-9413-f6b1dca6815a

History

Data availability:

Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

Read this article at

Related collections

Paul Drude Institute for Solid State Electronics (PDI)

Author and article information

Journal

Article

History

Comments

Comment on this article

Similar content 1,343

Cited by 4